Actively Recruiting
Correction of Psoriatic T Cell Signatures by Deucravacitinib
Led by University of California, San Francisco · Updated on 2026-06-04
25
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
Sponsors
U
University of California, San Francisco
Lead Sponsor
B
Bristol-Myers Squibb
Collaborating Sponsor
AI-Summary
What this Trial Is About
Researchers are evaluating how deucravacitinib, a Tyrosine kinase 2 (TYK2) blocker, affects immune cells in patients with moderate to severe psoriasis vulgaris. This Phase 4, open-label study involves 25 participants and aims to understand the changes in skin and blood immune cell function before and after treatment. Participants will receive deucravacitinib treatment for six months. During this time, skin biopsies and blood samples will be collected before starting treatment and during the treatment period. These samples will undergo molecular profiling to assess how deucravacitinib changes psoriatic T cell signatures. Throughout the study, participants will be monitored through biopsies, blood analysis, and clinical assessments including the Psoriasis Area and Severity Index (PASI) score, measured at baseline and after four months. The study focuses on safety and immune response changes during the six-month treatment period. Total participation time corresponds with the treatment duration and associated assessments.
CONDITIONS
Brief Title
Correction of Psoriatic T Cell Signatures by Deucravacitinib
Who Can Participate
Eligibility Criteria
You may qualify if you...
- 18 years of age or older
- Diagnosis of moderate to severe psoriasis with body surface area (BSA) of 10% or more
- Psoriasis Area and Severity Index (PASI) of 12 or higher
- Static Physician's Global Assessment (sPGA) score of 3 or above
You will not qualify if you...
- Use of systemic immunosuppressive drugs in the last 12 weeks
- Pregnancy
- Severe immunodeficiency from genetic or infectious causes
- Active tuberculosis or other serious infections
- Active systemic malignancy
- Breastfeeding
- Any condition or abnormality that may compromise patient safety or study data quality according to the Investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 6 months
Participants receive deucravacitinib treatment and undergo skin biopsy and blood sample collection before and during treatment for molecular profiling.
Visits for treatment and sample collection at baseline and mid-treatment
Trial Site Locations
Total: 1 location
1
University of California, San Francisco
San Francisco, California, United States, 94115
Actively Recruiting
Research Team
R
Raymond Cho, MD, PhD
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
BASIC_SCIENCE
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here